Drug Profile
Research programme: stem cell therapy - Rohto Pharmaceutical
Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Rohto Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified